Choosing a country will allow you to access local content and enable you to shop in your local currency.
Didn’t find your country? Please proceed to our International Site.
Applications & Technologies
We're Sorry.
Biochemical, structural, and functional characterization of potential drug targets is necessary for the discovery and development of therapeutics that modulate their activity in the desired way.
Our portfolio of specialist technologies provide researchers with valuable insights into a target’s involvement in disease pathology and a better understanding of the biological processes and key molecular pathways involved. These tools include cell imaging platforms, such as the IN Cell Analyzer high-content analysis system, and Biacore surface plasmon resonance technology for determination of the active binding concentration and characterization of unlabeled molecular interactions.
When screening for binders to orphan receptors (ligand fishing), Biacore systems detect specific binding directly in crude cell and tissue homogenates. The captured ligand can be recovered from the biosensor surface and the identity determined without further purification, saving both time and precious sample.
High-content analysis complements in vitro binding and enzyme assays. The technique is widely used to explore a target’s association with a specific disease, test its ability to regulate biological processes, and to confirm that interactions produce the desired effect in diseased cells. IN Cell Analyzer systems are ideally suited to large-scale assays including genome-scale RNAi screens which are used to identify sets of genes involved in specific mechanisms or to annotate those for which no clear role has previously been established.
Surface plasmon resonance (SPR) label-free technology facilitates detailed study of how lead compounds and antibodies bind to drug targets.
High-content analysis (HCA) gives deeper insights into how a drug or compound acts in a functional context providing for more information and confidence in both hit selection and safety and efficacy.
Biomolecular imagers for sensitive and quantitative digital imaging.
© 2012 General Electric Company doing business as GE Healthcare
We've detected that you're using an unsupported browser.You may continue browsing, but for the best experience, please use Mozilla Firefox (v.30+), Google Chrome (v.35+) or Internet Explorer (v.11+).
This website would like to place cookies on your computer to help us serve you better. To understand how we use cookies, please view our privacy policy.
